NXgenPort Announces Collaboration with Mayo Clinic

NXgenPort Announces Collaboration with Mayo Clinic
News provided by
Share this article
Share this article
MINNEAPOLIS and VENTURA, Calif., May 25, 2021 /PRNewswire/ -- NXgenPort, a biomedical technology company developing products to provide doctors with remote patient monitoring, announced today that it has entered into a license agreement with Mayo Clinic to advance development and product testing efforts.  
NXgenPort's medical device helps providers like Mayo Clinic monitor cancer patients at home with an implantable chemo-port catheter (patent pending). NXgenPort combines proven chemo-port efficacy with sensor technology to measure and remotely monitor early onset of complications by reporting and tracking patient response over the course of their treatment. According to the Chief Science Officer at NXgenPort, Dr. Rosanne Welcher, "NXgenPort will bring the benefits of remote patient monitoring to cancer patients, who may have limited support between their treatments. Advances in sensor technology are enabling better patient management in diabetes and heart function care – it is time for cancer patients to benefit as well." 

Related Keywords

Rosanne Welcher , Prnewswire Nxgenport , Tufia Haddad , Cathy Skinner , Digital Health , Product Development , Mayo Clinic Center , Mayo Clinic , Chief Science Officer , Medical Director , Nxgenport , கேத்தி ஸ்கின்னர் , டிஜிட்டல் ஆரோக்கியம் , ப்ராடக்ட் வளர்ச்சி , மயோ சிகிச்சையகம் மையம் , மயோ சிகிச்சையகம் , தலைமை அறிவியல் அதிகாரி , மருத்துவ இயக்குனர் ,